Outcome of Board Meeting including Unaudited Financial Results for the quarter and nine months ended December 31, 2025 as approved by the Board

Net loss reportedEBITDA margin compressionExceptional itemResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+6.6%Reaction day

₹76.00

prior close

₹78.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.5%+7.1% vs market

Other Financial Services peers, median of 80sector+0.0%+6.6% vs sector

On the reaction day the stock moved 7.1 pts more than Nifty Microcap 250 and 6.6 pts more than its Other Financial Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

+1.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+6.6-0.5+7.1+0.0+6.6

Next day

+9.9-2.0+11.8+0.0+9.9

+0.0-2.7+2.7-1.5+1.5

+0.0-1.7+1.7-0.7+0.7

+3.5-1.4+5.0-0.7+4.3

+2.5-2.8+5.3-2.1+4.6

+6.8-2.8+9.7-3.0+9.8

15d

-14.5-8.4-6.1-6.0-8.5

+4.6-9.1+13.7-6.6+11.2

-11.8-4.0-7.8-5.9-6.0

-1.3+2.6-4.0+0.4-1.7

UpDownMarket · Nifty Microcap 250Sector · Other Financial Services peers, median of 80Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Relic Technologies' Board approved unaudited financial results for Q3 FY26 and nine months ended December 31, 2025. On a standalone basis, the company reported no revenue from operations as its planned shift to pharma and wellness products is still awaiting regulatory approvals; standalone net profit stood at Rs. 17.38 lakhs for the quarter and Rs. 44.71 lakhs for 9M FY26, a swing from the prior year's loss of Rs. 147.49 lakhs. On a consolidated basis (including Relic Pharma Ltd and the recently acquired Truhealthy Wellness Pvt Ltd), revenue from operations grew about 46% year-on-year to Rs. 220.07 lakhs for 9M FY26, but the company posted a net loss of Rs. 400.79 lakhs for 9M, hit by Rs. 232.12 lakhs of exceptional items and a sharp jump in employee benefit expenses (from Rs. 22.73 lakhs to Rs. 333.38 lakhs). Statutory auditor D. Kothary & Co. issued an unmodified review opinion on both sets of results. Additionally, 4,41,164 warrants were converted into equity shares, raising paid-up capital from Rs. 360 lakhs to Rs. 559.12 lakhs.

Likely market impact

Mixed picture for shareholders: standalone turned profitable but the consolidated business is loss-making as subsidiary operations ramp up, with significantly higher employee and operating costs pressuring margins. The warrant-driven equity infusion is constructive for the balance sheet, but near-term consolidated profitability remains a concern pending revenue scale-up from the pharma and wellness subsidiaries.